Ncardia (BE, HQ)

https://www.ncardia.com

Twitter: @NcardiaStemCell

Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. The company’s goal is to enable biopharmaceutical companies in drug discovery and cell therapy to accelerate their development processes through the integration of human iPSC technologies. Following the formation of a strategic partnership with Kiniciti, including a $60 million investment, Ncardia is globally expanding its drug discovery and cell therapy services by developing more robust offerings, building GMP capabilities and developing allogeneic immune cell manufacturing platforms. *

	Start	2017-09-18 merged
	Group	Kiniciti Bio (WCAS invesment platform) (Group)
	Predecessor	Axiogenesis AG
	Industry	iPSC technology (induced pluripotent stem cell technology)
	Industry 2	assay, research
	Person	Braam, Stefan (Ncardia 201709– CEO before Pluriomics)
	Person 2	Bohlen, Heribert (Axiogenesis 201603 CEO)

	Region	Gosselies
	Country	Belgium
	Street	47 Rue Adrienne Bolland
	City	6041 Gosselies
		Address record changed: 2020-12-02

Basic data	Employees	C: 51 to 100 (2017-09-18)

		* Document for ï¿½About Sectionï¿½: Ncardia Services B.V.. (2/24/22). "Press Release: Ncardia Appoints Andy Holt as Chief Commercial Officer". Leiden.

		Record changed: 2022-05-02